cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Finch Therapeutics Group Inc
11 own
16 watching
Current Price
$0
$-0.01
(-4.42%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
13.72M
52-Week High
52-Week High
3
52-Week Low
52-Week Low
0.2505
Average Volume
Average Volume
0.16M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization13.72M
icon52-Week High3
icon52-Week Low0.2505
iconAverage Volume0.16M
iconDividend Yield--
iconP/E Ratio--
What does the Finch Therapeutics Group Inc do?
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company s lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Read More
How much money does Finch Therapeutics Group Inc make?
News & Events about Finch Therapeutics Group Inc.
Globe Newswire
1day ago
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch, Finch Therapeutics or the Company) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its ...
Zolmax
2 months ago
Atara Biotherapeutics (NASDAQ:ATRA Get Rating) and Finch Therapeutics Group (NASDAQ:FNCH Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, ...
Globe Newswire
4 months ago
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the Company, Finch, or Finch Therapeutics) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of ...
Globe Newswire
7 months ago
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today ...
Zolmax
7 months ago
Finch Therapeutics Group, Inc. (NASDAQ:FNCH Get Rating) traded down 3% on Friday . The company traded as low as $1.58 and last traded at $1.59. 11,318 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 344,381 shares. The stock had previously closed at $...
Frequently Asked Questions
Frequently Asked Questions
What is Finch Therapeutics Group Inc share price today?
plus_minus_icon
Can Indians buy Finch Therapeutics Group Inc shares?
plus_minus_icon
How can I buy Finch Therapeutics Group Inc shares from India?
plus_minus_icon
Can Fractional shares of Finch Therapeutics Group Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Finch Therapeutics Group Inc stocks?
plus_minus_icon
What is today’s traded volume of Finch Therapeutics Group Inc?
plus_minus_icon
What is today’s market capitalisation of Finch Therapeutics Group Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Finch Therapeutics Group Inc?
plus_minus_icon
What percentage is Finch Therapeutics Group Inc down from its 52-Week High?
plus_minus_icon
What percentage is Finch Therapeutics Group Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.01
(-4.42%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$0.36
$0.05 (17.84 %)
Humanigen Inc
Humanigen Inc
$0.14
$0.00 (-0.69 %)
I-Mab
I-Mab
$3.15
$-0.03 (-0.94 %)
Immutep Ltd
Immutep Ltd
$2.06
$0.01 (0.49 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$0.36
$0.05 (17.84 %)
Humanigen Inc
Humanigen Inc
$0.14
$0.00 (-0.69 %)
I-Mab
I-Mab
$3.15
$-0.03 (-0.94 %)
Immutep Ltd
Immutep Ltd
$2.06
$0.01 (0.49 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00